Standard table direct anterior approach within an early discharge protocol for cementless total hip arthroplasty: experience from a Japanese hospital.
Authors: Nakakita Y, Bourcet A, Mantel J, Park H, Rossi A, Oinuma K, Shiratsuchi H Abstract AIMS: Clinical and economic outcomes associated with an early discharge protocol for cementless total hip arthroplasty (THA) via a direct anterior approach (DAA) on a standard table without a dedicated traction table) were assessed. These outcomes were compared against a benchmark of THA care approximated from a national database. MATERIALS AND METHODS: This retrospective, observational, comparative cohort study evaluated 250 patients receiving THA with a standard table DAA approach under an early discharge protocol at a...
Source: Journal of Medical Economics - February 23, 2021 Category: Health Management Tags: J Med Econ Source Type: research

A pragmatic methodology for the evaluation of digital care management in the context of multimorbidity.
We describe here a novel and pragmatic methodology for the evaluation of digital care management that is generalizable to any longitudinal intervention for multimorbidity irrespective of its mode of delivery. This methodology implements propensity matching with bootstrapping to address some of the major challenges in evaluation including identification of robust outcome measures, selection of an appropriate control population, small sample sizes with class imbalances, and limitations of RCTs. We apply this methodology to the evaluation of digital care management at a U.S. payor and demonstrate a 9% reduction in ER utilizat...
Source: Journal of Medical Economics - February 18, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine.
Authors: Huang H, Schmerold L, Dembek C, Fan Q, Dieyi C, Williams GR, Loebel A Abstract OBJECTIVE: To compare healthcare resource utilization (HCRU), costs, and treatment adherence and persistence for patients with bipolar disorder treated with lurasidone or cariprazine. METHODS: Adult patients with bipolar disorder who initiated lurasidone or cariprazine as monotherapy or adjunctive therapy between 1/1/2016 and 6/30/2019 were identified from the IBM MarketScan Commercial and Medicare Supplemental Database. The date of the first claim for lurasidone or cariprazine was defined as the index date. A difference-in-...
Source: Journal of Medical Economics - February 18, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Adult lifetime cost of hemophilia B management in the US: Payer and societal perspectives from a decision analytic model.
CONCLUSIONS: This decision analytic model demonstrated significant economic burden associated with the current HB treatment paradigm. PMID: 33591884 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 18, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Antiviral Use Is Associated with a Decrease in the Rate of Influenza-Related Complications, Health Care Resource Utilization, and Costs.
Authors: Wallick C, Wu N, To TM, Keebler D, Moawad D Abstract AIMS: To determine the effect of antiviral agents on influenza-related complications, healthcare resource utilization (HRU), and costs over 3 influenza seasons (2014-2016). METHODS: This retrospective cohort study used claims data from the U.S. MarketScan Research Databases. Patients with a diagnosis code for influenza during the 2014-2016 seasons in an outpatient setting, with continuous enrollment from 1 year before to 91 days after diagnosis, were included. Patients who received an antiviral within 48 hours of diagnosis were identified and ...
Source: Journal of Medical Economics - February 13, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
CONCLUSIONS: Compared to regorafenib, fruquintinib, which leads to forego about 0.05 QALYs and save about CNY 75,599 (USD 11,454), is a cost-effective choice as the third-line treatment for patients with metastatic colorectal cancer in China. PMID: 33571036 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 13, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Incidence, predictors, and economic burden of circular anastomotic complications in left-sided colorectal reconstructions involving manual circular staplers.
Authors: Fortin SP, Johnston SS, Chaudhuri R, Fryrear R, Roy S Abstract STUDY AIM: Manual circular staplers are widely used in colorectal surgery; however, limited literature exists examining complications related to circular anastomoses when such devices are used. The present study evaluated the incidence, predictors, and economic burden of circular anastomotic complications in left-sided colorectal reconstructions involving manual circular staplers. MATERIALS AND METHODS: Patients aged ≥18 years who underwent hemicolectomy, low anterior resection, or sigmoidectomy between October 1, 2016-December 31, 2018 ...
Source: Journal of Medical Economics - February 13, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US.
Authors: Kong AM, Pavilack M, Huo H, Shenolikar R, Moynihan M, Marchlewicz EH, Chebili-Larson C, Min S, Subramaniam DS Abstract BACKGROUND: Non-small cell lung cancer (NSCLC) with brain metastases (BM) is difficult to treat and associated with poor survival. We assessed the impact of BM on healthcare-related utilization and costs (HRUC) among patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). PATIENTS AND METHODS: Adults newly-diagnosed with metastatic NSCLC, initiating first-/second-generation EGFR-TKI treatment, with BM or no BM (NBM), were identified retrospectively f...
Source: Journal of Medical Economics - February 13, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Modeling the Economic Value of Ceribell Rapid Response EEG in the Inpatient Hospital Setting.
CONCLUSIONS: Rapid-EEG alters the treatment course for patients with suspected seizures and will likely result in cost savings per patient. PMID: 33560905 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 10, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Health outcomes and economic burden of hospitalized COVID-19 patients in the United States.
CONCLUSIONS: This study summarizes the severe health outcomes and substantial hospital costs of hospitalized COVID-19 patients in the US. The findings support the urgent need for rapid implementation of effective interventions, including safe and efficacious vaccines. PMID: 33555956 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 9, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Budget impact analysis: can we afford the added value?
Authors: Petrou P PMID: 33544634 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 8, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Burden of caring for Alzheimer's disease or dementia patients in Japan, US, and EU: results from the National Health and Wellness Survey: a cross-sectional survey.
CONCLUSIONS: The caregiving burden among AD/dementia caregivers were substantial across the three regions, with similarities and differences between the West and Japan. The lower caregiving burden in Japan was potentially associated with national policies supporting long-term healthcare and institutionalized nursing care facilities for AD/dementia patients. PMID: 33538195 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 6, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
CONCLUSION: At the 12-month landmark, P + A suggests better economic scenario versus N + I as first-line mRCC treatment option for intermediate- and poor-risk groups, through an indirect comparison using sunitinib as a common comparator. PMID: 33538203 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 6, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Influence of neurovascular embolic coil primary wind diameter on aneurysm packing density and case costs.
CONCLUSIONS: Coil PWD influences packing density, the number of coils required to achieve a specific packing density, and total case costs. Using 0.012" PWD coils may provide cost and procedural efficiencies. PMID: 33539185 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 6, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare costs before and after stroke in non-valvular atrial fibrillation patients who initiated treatment with rivaroxaban or warfarin.
This study compared healthcare costs before and after stroke in NVAF patients treated with rivaroxaban or warfarin. MATERIALS AND METHODS: Using de-identified IBM® MarketScan® Commercial and Medicare databases, this retrospective cohort study (from 2011-2019) included patients with NVAF who initiated rivaroxaban or warfarin within 30 days after initial NVAF diagnosis. Patients who developed stroke were identified, and stroke severity was determined by the National Institutes of Health Stroke Scale (NIHSS) score, imputed by a random forest method. Total all-cause per-patient per-year (PPPY) costs of care were de...
Source: Journal of Medical Economics - January 29, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
CONCLUSIONS: The results of this economic model suggest tofacitinib is a cost-effective treatment option for patients with moderate-to-severe UC in Germany. PMID: 33502905 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 29, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.
This study evaluated infection-related hospitalization risk and cost in tumor necrosis factor inhibitor (TNFi)-experienced and targeted DMARD (tDMARD) naïve rheumatoid arthritis (RA) patients that were treated with abatacept, TNFi, or other non-TNFi. METHODS: This retrospective study used 100% Medicare Fee-for-Service claims to identify patients ≥65 age, diagnosed with RA, and were either 1) TNFi-experienced, who switched from a TNFi to another tDMARD (subsequent tDMARD claim served as index), or 2) tDMARD naïve (first therapy claim served as index), who initiated either abatacept, TNFi, or non-TNFi as the...
Source: Journal of Medical Economics - January 29, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndrome Treated with Hypomethylating Agents: A SEER-Medicare Analysis.
CONCLUSIONS: Over 75% of patients with MDS failed HMA-treatment within 6 months of initiation and were observed with more inpatient admissions than those with HMA-treatment success, translating into substantially higher healthcare costs. HMA-treatment failure results in an important economic burden in MDS patients. PMID: 33472483 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 23, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Willingness to pay for primary health care at public facilities in the Western Cape Province, Cape Town, South Africa.
CONCLUSION: This study revealed factors related to the participants' WTP and to their willingness to contribute towards the health service, though at very low amounts. Understanding the economic value placed upon a service provided in a facility is essential in decision-making for quality care improvements, especially as the South African health system is making the facilities ready for NHI. PMID: 33476214 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 23, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Estimating the Preferences and Willingness-To-Pay for Colorectal Cancer Screening: An Opportunity to Incorporate the Perspective of Population at Risk into Policy Development in Thailand.
This study aims to examine the preferences and willingness-to-pay of a population at risk for CRC screening in Thailand. Understanding the preferences for these individuals at risk would help Thailand, as an example of LMICs, to design effective population-based CRC screening programs. MATERIALS AND METHODS: A discrete choice experiment (DCE) was conducted among screening-naïve adults aged 50-75 years, who were at risk of CRC, in the out-patient department of a tertiary care hospital in Thailand. A DCE questionnaire was developed from six CRC screening attributes. Each questionnaire was composed of six choice sets...
Source: Journal of Medical Economics - January 21, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Humanistic burden among caregivers of patients with Alzheimer's disease or dementia in Japan: a large-scale cross-sectional survey.
CONCLUSIONS: Caregivers of AD/dementia patients in Japan reportedly experienced significant humanistic burden which is associated with patients' living arrangements and presence of additional chronic condition. Therefore, provision of effective care/support is essential to relieve the burden experienced by the caregivers. PMID: 33467967 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 21, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis.
CONCLUSIONS: The results suggest that-among the antivirals approved in Japan-the monetary value of the utility is the highest in the single dose oral antiviral, baloxavir marboxil (baloxavir). Although the drug cost was highest in baloxavir among the brand antivirals, the difference in the value of utility for influenza patient was estimated to be larger than the difference in the drug costs. LIMITATIONS: Although individuals with diverse attributes from all over the country were included in the survey, they are not necessarily a representative population of the Japanese. PMID: 33470138 [PubMed - as supplied by pub...
Source: Journal of Medical Economics - January 21, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Comparison of cost-effectiveness of implantable cardioverter defibrillator therapy in patients for primary prevention in Latin America: an analysis using the Improve SCA Study.
Authors: Higuera L, Holbrook R, Wherry K, Rodriguez DA, Cuesta A, Valencia J, Arcos J, López Gómez A Abstract OBJECTIVE: The mortality benefit of implantable cardioverter defibrillators (ICDs) for primary prevention (PP) of sudden cardiac arrest (SCA) has been well-established, but ICD therapy remains globally underutilized. The results of the Improve SCA study showed a 49% relative risk reduction in all-cause mortality among ICD patients with 1.5 primary prevention (1.5PP) characteristics (patients with one or more risk factors, P
Source: Journal of Medical Economics - January 21, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Budget impact analysis of Jivi ® (damoctocog alfa pegol, BAY 94-9027) in severe Hemophilia A in Japan.
CONCLUSIONS: BAY 94-9027 can reduce total severe HA treatment costs, driven by lower annual rFVIII utilization, and a narrow weekly dosing range compared to competitor products in the Japanese market. PMID: 33459088 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
CONCLUSIONS: Though uncertainties remain with the generated PFS curve, the derived azacitidine curves, administration and vial wastage, the model has been built under the best available evidence and relied on clinical opinions where there were data gaps. The weighted average ICER suggests that glasdegib + LDAC is cost-effective at a CAD $100,000 willingness-to-pay threshold. PMID: 33461352 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
CONCLUSIONS: The economic burden of PPMS was estimated at AU$418 million in 2018. An effective DMT that delayed progression from disease severity states by one year could provide significant cost savings. PMID: 33461357 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
CONCLUSIONS: Applying a cross-sectorial government perspective budget impact assessment improves our understanding of fiscal changes attributed to ASCVD based on changes in premature mortality and work activity and how this influences lifetime tax contributions and public benefits. The main cost driver observed was associated with reduced ASCVD events that enabled people to remain productive and paying taxes. PMID: 33464137 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
Authors: Volk ML, Burne R, Guérin A, Shi S, Joseph G, Heimanson Z, Ahmad M Abstract AIMS: To assess healthcare costs and hospitalization rates associated with rifaximin therapy versus lactulose alone among patients at risk for hepatic encephalopathy (HE). METHODS AND MATERIALS: IBM Marketscan® Commercial and Optum's de-identified Clinformatics® Data Mart databases were used separately to identify commercially insured HE patients treated with rifaximin or lactulose alone, using an algorithm developed with clinical experts. HE-related hospitalizations were defined based on an algorithm using diagno...
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Excess Healthcare Costs in Patients with Autosomal Dominant Polycystic Kidney Disease by Renal Dysfunction Stage.
Authors: Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Guérin A, Cloutier M Abstract AIM: To build upon previous outdated studies by comprehensively assessing the direct healthcare burden of autosomal dominant polycystic kidney disease (ADPKD). MATERIALS AND METHODS: Patients with ≥2 diagnoses for ADPKD (ADPKD cohort) were identified in the US fee-for-use IBM Truven Health Analytics MarketScan® Commercial Claims and Encounters and IBM Truven Health Analytics MarketScan® Medicare Supplemental databases (01/01/2015-12/31/2017) and matched (1:3) to controls without ADPKD (non-ADPKD cohort)....
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Long-term cost-effectiveness of a disease management program for patients with atrial fibrillation compared to standard care - a multi-state survival model based on a randomized controlled trial.
CONCLUSIONS: The SAFETY program has a high probability of being cost-effective for patients with atrial fibrillation. It is associated with uncertainty that further research could potentially eliminate; implementation with further evidence collection is recommended. PMID: 33406944 [PubMed - in process] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 9, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States.
CONCLUSIONS: The estimated budget impact of including capmatinib for mNSCLC with a METex14 skipping mutation is minimal, and the increased drug costs were partially offset by savings in AEs, and progression-related and terminal care costs. PMID: 33397178 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 7, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
CONCLUSIONS: Anti-myeloma drugs were the main contributor to total HRU costs associated with RRMM in Germany. Improved treatment response was associated with lower costs and reduced hospitalizations. PMID: 33390079 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 6, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
Conclusions : In patients with TD, treatment with valbenazine is highly cost-effective compared with deutetrabenazine. PMID: 33393412 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 6, 2021 Category: Health Management Tags: J Med Econ Source Type: research

A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
CONCLUSIONS: Mixture cure modeling was equivalent compared to parametric modeling in estimating the cost-effectiveness of nivolumab-based therapy due to the small fraction of patients achieving a long-term response with nivolumab (12.9%). PMID: 33334176 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 20, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina.
CONCLUSION: Universal FLS implementation in Brazil, Mexico, Colombia, and Argentina was predicted to prevent 31,400 fractures, avoid 292,281 bed days, and save 58.4 million USD in 2019, though caution is warranted in the interpretation of these results due to high uncertainty. Increased implementation of FLS programs in Latin American countries may help to realize these benefits. PMID: 33334205 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 20, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Evaluation of access to care issues in patients with breast cancer.
This study examined access to care in a population of women with breast cancer and its relationship to overall patient satisfaction. MATERIALS AND METHODS: Patients with breast cancer from six oncology clinics in five states completed a survey during routine office visits. Access to care (higher scores indicated increasing access barriers), overall patient satisfaction, and patient demographic/clinical characteristics were measured. The relationships between access (composite and factor scores) and satisfaction were assessed using multivariable analyses controlling for age (the only significant characteristic from biva...
Source: Journal of Medical Economics - December 17, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database.
This study developed a claims-base disability score (CDS) based on the EDSS for assigning MS disability level in a U.S. claims database. METHODS: This retrospective cohort study of patients with MS in the U.S., utilized adjudicated health plan claims data linked to electronic medical records (EMR) data. Patients were identified between 01 January 2012 and 31 December 2016 and indexed on the first date of MS diagnosis. The CDS was developed to assign disability level at baseline using claims and ambulatory EMR records observed over the 1-year baseline period. All-cause healthcare costs were assessed by baseline disabili...
Source: Journal of Medical Economics - December 13, 2020 Category: Health Management Tags: J Med Econ Source Type: research

A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a U.S. health plan.
CONCLUSIONS: Adding gilteritinib to the formulary for the treatment of adults with R/R FLT3 mut+ AML had a minimal budget impact from a U.S. payer's perspective. PMID: 33280474 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 8, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization and costs for hip dislocation following primary total hip arthroplasty in the Medicare population.
CONCLUSIONS: This large U.S. retrospective database study demonstrated the substantial HCRU and cost burden of THA dislocation. PMID: 33267624 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder.
CONCLUSIONS: Depending on the payer's willingness to pay, reSET-O may be cost-effective in increasing buprenorphine treatment retention rates. reSET-O results in an approximate budget impact of $0.003 per member per month, depending on market share and the prevalence of the population receiving treatment for OUD. PMID: 33267633 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Effect of direct oral feeding following minimally invasive esophagectomy on costs and quality of life.
CONCLUSION: This study suggests that direct oral feeding leads to similar total costs and a significantly reduced need for home care assistance. Furthermore, QoL in intervention group increased more quickly when compared to the control group. PMID: 33274674 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis.
CONCLUSION: Based on the analysis of incremental cost per QALY gained, GT is may be cost-effective relative to prescription aluminum chloride at commonly accepted willingness to pay thresholds. PMID: 33256494 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 3, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Iran, sanctions, and the COVID-19 crisis.
In conclusion, providing health services is one of the major problems of Iran's health system during this pandemic that potentially influence on morbidity and mortality of the COVID-19. Iran needs to be free from sanctions for battling against this crisis. Key messages: Iran is one of the countries that significantly impacted by the COVID-19 pandemic. Iran is under political and economic sanctions that consequently influence on their health system during the COVID-19 crisis. The chronic and long-term effects of sanctions may be more tangible than their acute impact. PMID: 33249954 [PubMed - as supplied by publisher] (S...
Source: Journal of Medical Economics - December 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research

An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK.
We present an economic model structure suitable for comparing interventions used in MR and TR, and assess the cost-effectiveness of transcatheter mitral valve repair (TMVr) plus guideline directed medical therapy (GDMT) compared with GDMT alone in people with MR. Methods: An economic model with a lifetime time horizon was developed based on extrapolated survival data and using New York Heart Association classifications to describe disease severity in people with functional MR at high risk of surgical mortality or deemed inoperable. Cost and utility values (describing health related quality of life) were assigned to patient...
Source: Journal of Medical Economics - November 27, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Corneal cross-linking versus conventional management for keratoconus: a lifetime economic model.
CONCLUSIONS: Keratoconus is a progressive and life-altering disease with substantial clinical, economic, and humanistic consequences. The economic value of cross-linking is maximized when applied earlier in the disease process and/or younger age, and extends to improved work productivity, out-of-pocket costs, and quality of life. PMID: 33210975 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 21, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Key patient related factors in the management of inflammatory bowel disease.
Authors: Allocati E, Godman B PMID: 33210979 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 21, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.
Conclusions. Letermovir prophylaxis would be cost-effective for preventing CMV infection in adult seropositive allogeneic HSCT recipients in Hong Kong. PMID: 33155494 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 11, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016.
Authors: MacEwan JP, Dennen S, Kee R, Ali F, Shafrin J, Batt K Abstract AIMS: To estimate the extent to which the approvals of new pharmacological therapies were associated with cancer mortality in the USA between 2000 and 2016. MATERIALS AND METHODS: The analysis quantified cancer drug approvals across the 15 tumor types with the highest incidence. Number of approvals in a given time period for each tumor was translated into a treatment stock measure, defined as a weighted sum of new indication approvals since 1976. The primary outcome was the annual tumor-specific cancer mortality, defined as the number of de...
Source: Journal of Medical Economics - November 11, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with glycopyrrolate/eFlow ® in the US: A real-world data analysis.
This study compared medication use, healthcare resource utilization (HRU), and exacerbations among individuals with chronic obstructive pulmonary disease (COPD) who initiated glycopyrrolate/eFlow® Closed System nebulizer 25 mcg/mL glycopyrrolate (hereafter GLY/eFlow) in a real-world setting before and after treatment initiation. MATERIALS AND METHODS: Retrospective claims and hospital charge master data were used to identify individuals ≥40 years of age diagnosed with COPD who initiated GLY/eFlow between April 1, 2018 and February 28, 2019 (first prescription claim = index date). Patients we...
Source: Journal of Medical Economics - November 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
This study assesses the cost-effectiveness (CE) of palivizumab in premature infants with and without risk factors for hospitalization (congenital heart disease [CHD], bronchopulmonary dysplasia [BPD]). METHODS: A decision tree model, based on earlier CE analyses, was updated using data derived from targeted literature reviews and advice gained from a Round Table meeting. All costs were updated to 2019 prices. One-way and probabilistic sensitivity analyses were performed to assess the degree of uncertainty surrounding the results. RESULTS: Palivizumab is dominant (i.e. clinically superior and cost saving) when used ...
Source: Journal of Medical Economics - October 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research